Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

der(6)t(1;6)(q21-23;p21)

Written2010-03Adriana Zamecnikova
Kuwait Cancer Control Center, Laboratory of Cancer Genetics, Department of Hematology, Shuwaikh, 70653, Kuwait

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
ICD-Morpho 9975/3 Chronic myelogenous leukaemia, BCR-ABL1 positive; Myeloproliferative neoplasm, unclassifiable; Myelodysplastic/myeloproliferative neoplasm, unclassifiable
Atlas_Id 1546
 
  Partial karyotypes showing the chromosomal translocation der(6)t(1;6)(q21-23;p21) identified by G-banding.

Clinics and Pathology

Disease Most frequently observed in chronic myeloproliferative disorders, occurs with higher frequency in patients with chronic idiopathic myelofibrosis, polycythemia vera and post-polycythemic myelofibrosis; may be present either at diagnosis or during transformation to advanced stages of the disease.
Epidemiology Described in 20 cases (11 males, 9 females): 1 biphenotypic leukemia (16 years old male); 1 B-cell lymphoma (73 years old female); 2 acute myeloid leukemia (AML) patients (1 male 71 years old, 1 female 28 years old); and in 16 patients with myelofibrosis with myeloid metaplasia (9 males; 7 females): eleven patients had myelofibrosis with myeloid metaplasia, three post-polycythemic myeloid metaplasia, and one post-thrombocythemic myeloid metaplasia; one of these patients, a 47 years old male, progressed to AML. From the known data of 14 patients with myelofibrosis, median age was 65.5 years (range, 38-72 years).
Clinics In the largest study, the anomaly was associated with splenomegaly, elevated WBC count, elevated levels of alkaline phosphatase and lactate dehydrogenase; median overall survival was 7.8 years: five patients have died (one transformed to acute myeloid leukemia and the others died because of sepsis or thrombosis).

Cytogenetics

Cytogenetics Morphological Breakpoints may be controversial and difficult to ascertain in poor quality preparations. Recently, the same breakpoint on 6p21.3 and clustering of breakpoints near the paracentric region 1q21-23 was described in 14 patients with myelofibrosis with myelocytic metaplasia.
Additional anomalies Sole anomaly in 9 cases (2 AML and 7 cases with myelofibrosis); no recurrent additional anomaly observed in patients with complex karyotypes. 4 patients had two or more different clones (1 patient with biphenotypic leukemia and 3 myelofibrosis cases); among them 2 patients had 1q21-23 rearrangements involving the homologous chromosome 1.

Result of the chromosomal anomaly

Fusion Protein
Oncogenesis The presence of the der(6)t(1;6) results in partial trisomy for 1q21-23 to 1qter and in loss of 6p21 to 6pter. The pathogenetic significance may be the consequence of gain of gene(s) on 1q and/or haplo-insufficiency of gene(s) from 6p and alternatively, rearrangements of one or more genes at the breakpoints. The significance of the 6p21 breakpoint is unclear; however a number of published reports of myelofibrosis with chromosome 6p breakpoints in the region raise the possibility of a gene involved in the pathogenesis of this hematologic disorder. The inability to identify common breakpoints on 1q, suggests that an increase in gene copy number is a pathogenetic event. Whether trisomy 1q is a secondary event to a primary (cryptic? e.g. JAK2 V617F mutation) anomaly as well as the roles of methylation, cytotoxic treatments and the underlying molecular consequences of the rearrangement remain to be determined.
  

To be noted

Case Report der(6)t(1;6)(q21;p21) in myelofibrosis following polycythemia vera

Bibliography

Karyotypic abnormalities in myelofibrosis following polycythemia vera.
Andrieux J, Demory JL, Caulier MT, Agape P, Wetterwald M, Bauters F, Lai JL.
Cancer Genet Cytogenet. 2003 Jan 15;140(2):118-23.
PMID 12645649
 
Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia.
Dingli D, Grand FH, Mahaffey V, Spurbeck J, Ross FM, Watmore AE, Reilly JT, Cross NC, Dewald GW, Tefferi A.
Br J Haematol. 2005 Jul;130(2):229-32.
PMID 16029451
 
Conventional cytogenetics in myelofibrosis: literature review and discussion.
Hussein K, Van Dyke DL, Tefferi A.
Eur J Haematol. 2009 May;82(5):329-38. Epub 2009 Jan 9.
PMID 19141119
 
Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature.
Mertens F, Johansson B, Heim S, Kristoffersson U, Mitelman F.
Leukemia. 1991 Mar;5(3):214-20.
PMID 2013980
 
Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases.
Reilly JT, Snowden JA, Spearing RL, Fitzgerald PM, Jones N, Watmore A, Potter A.
Br J Haematol. 1997 Jul;98(1):96-102.
PMID 9233570
 

Citation

This paper should be referenced as such :
Zamecnikova, A
der(6)t(1;6)(q21-23;p21)
Atlas Genet Cytogenet Oncol Haematol. 2010;14(12):1175-1176.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Anomalies/der6t0106q21p21ID1546.html


Translocations implicated (Data extracted from papers in the Atlas)

 der(6)t(1;6)(q21;p21)

External links

Mitelman databaseder(6)t(1;6)(q21;p21) [Case List]    der(6)t(1;6)(q21;p21) [Association List] Mitelman database (CGAP - NCBI)
arrayMapTopo ( C42) Morph ( 9975/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
 
 
Disease databaseder(6)t(1;6)(q21-23;p21)
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Thu Jan 12 11:17:35 CET 2017


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.